Equities Research Analysts’ Updated EPS Estimates for May, 27th (ARCE, ARMP, ARVN, ASLN, ATASY, ATEN, BAESY, BANX, BCAUY, BTVCY)

Share on StockTwits

Equities Research Analysts’ updated eps estimates for Monday, May 27th:

Arco Platform (NASDAQ:ARCE) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Arco Platform Limited develops educational software. The Company offers a platform which delivers educational content in printed and digital formats. Arco Platform Limited is based in Vila Olimpia Sao Paulo, Brazil. “

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) was upgraded by analysts at Zacks Investment Research from a sell rating to a buy rating. Zacks Investment Research currently has $3.50 target price on the stock. According to Zacks, “Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company’s principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. “

Arvinas (NASDAQ:ARVN) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States. “

ASLAN PHARMACEU/ADR (NASDAQ:ASLN) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company’s product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003 both are in clinical stage. ASLAN Pharmaceuticals Limited is based in Singapore. “

ATLANTIA SPA/ADR (OTCMKTS:ATASY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Atlantia S.p.A. is a holding company with responsibility for portfolio strategies in the transport and communications infrastructures and network sectors. The company builds and operates toll motorways in Italy and internationally. Atlantia is based in Roma, Italy. “

A10 Networks (NYSE:ATEN) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “A10 Networks, Inc. provides software based application networking solutions. Its solutions enable enterprises, service providers, Web giants, and government organizations to enhance, secure, and optimize the performance of their data center applications and networks. The company delivers its solutions on optimized hardware appliances and as virtual appliances across its Thunder Series and AX Series product families. A10 Networks, Inc. is headquartered in San Jose, California. “

BAE SYS PLC/S (OTCMKTS:BAESY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “BAE Systems is a global company engaged in the development, delivery and support of advanced defence and aerospace systems in the air, on land and at sea. BAE Systems Inc. is the US subsidiary of BAE Systems plc. Headquartered in Rockville,Maryland, BAE Systems Inc. consists of three Operating Groups that provide support and service solutions for current and future defense, intelligence, and civilian systems; design, develop and manufacture a wide range of electronic systems and subsystems for both military and commercial applications; and design, develop, produce,and provide service support of armored combat vehicles, artillery systems and intelligent munitions. “

StoneCastle Financial (NASDAQ:BANX) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “StoneCastle Financial Corp. is a closed-end investment company. It invests in community banks located throughout the United States. The Company’s primary investment objective is to provide stockholders with current income, and to a lesser extent, capital appreciation, through preferred equity, subordinated debt and common equity investments predominantly in U.S. domiciled community banks. StoneCastle Financial Corp. is based in United States. “

Brilliance China Automotive (OTCMKTS:BCAUY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Brilliance China Automotive Holdings Limited operates as an automotive manufacturer in China. The Company’s operating segments are divided primarily into the manufacture and sale of minibuses and automotive components. Its commercial vehicle brands include JinBei and Granse minibuses. The Group is also engaged in the manufacture of diesel engines and gasoline engines for use in minibuses, sedans, SUV and light duty trucks and automotive components. Brilliance China Automotive Holdings Limited is headquartered in Central, Hong Kong. “

BRITVIC PLC/S (OTCMKTS:BTVCY) was upgraded by analysts at Investec from a hold rating to a buy rating.

FibroGen (NASDAQ:FGEN) had its positive rating reissued by analysts at Piper Jaffray Companies. Piper Jaffray Companies currently has a $40.00 target price on the stock, down from their previous target price of $65.00.

Hibbett Sports (NASDAQ:HIBB) had its target price raised by Bank of America Corp from $18.00 to $20.00. The firm currently has an underperform rating on the stock.

BMO Capital Markets assumed coverage on shares of Parkland Fuel (OTCMKTS:PKIUF). The firm issued an outperform rating on the stock.

SINA (NASDAQ:SINA) had its target price cut by Bank of America Corp from $120.00 to $108.00. The firm currently has a buy rating on the stock.

Receive News & Ratings for Arco Platform Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arco Platform Ltd and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

AvalonBay Communities Inc Expected to Earn Q3 2019 Earnings of $2.32 Per Share
AvalonBay Communities Inc Expected to Earn Q3 2019 Earnings of $2.32 Per Share
Q3 2019 EPS Estimates for Boston Properties, Inc.  Lifted by Jefferies Financial Group
Q3 2019 EPS Estimates for Boston Properties, Inc. Lifted by Jefferies Financial Group
Newcardio  and Natus Medical  Head-To-Head Review
Newcardio and Natus Medical Head-To-Head Review
Red River Bancshares  and Guaranty Federal Bancshares  Critical Contrast
Red River Bancshares and Guaranty Federal Bancshares Critical Contrast
United Utilities Group  & Its Peers Head-To-Head Review
United Utilities Group & Its Peers Head-To-Head Review
Cinemark Holdings, Inc. Forecasted to Post Q3 2019 Earnings of $0.51 Per Share
Cinemark Holdings, Inc. Forecasted to Post Q3 2019 Earnings of $0.51 Per Share


© 2006-2019 Ticker Report